Compare TRX & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | CVRX |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 221.2M |
| IPO Year | N/A | 2021 |
| Metric | TRX | CVRX |
|---|---|---|
| Price | $0.86 | $8.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.25 | ★ $13.17 |
| AVG Volume (30 Days) | ★ 1.4M | 202.6K |
| Earning Date | 01-13-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $57,613,000.00 | $55,969,000.00 |
| Revenue This Year | $28.16 | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | $363.98 | ★ N/A |
| Revenue Growth | ★ 39.98 | 18.44 |
| 52 Week Low | $0.27 | $4.30 |
| 52 Week High | $0.89 | $18.55 |
| Indicator | TRX | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.56 | 37.60 |
| Support Level | $0.70 | $8.23 |
| Resistance Level | $0.89 | $8.93 |
| Average True Range (ATR) | 0.05 | 0.53 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 89.31 | 15.42 |
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.